Last Update 12:27
Friday, 14 May 2021

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Reuters , Thursday 7 May 2020
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the inves
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. (Reuters)
Share/Bookmark
Share/Bookmark

Japan has approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country's first officially authorised drug for the disease.

Japan reached the decision just three days after the U.S. drugmaker had filed for approval.

Remdesivir was granted authorisation last week by the U.S. Food and Drug Administration for emergency use for the disease caused by the coronavirus.

Short link:

 

Latest

© 2010 Ahram Online.